Chronic, Twice-Daily Dosing of an NK2 Receptor Agonist [Lys


Journal

Journal of neurotrauma
ISSN: 1557-9042
Titre abrégé: J Neurotrauma
Pays: United States
ID NLM: 8811626

Informations de publication

Date de publication:
15 03 2020
Historique:
pubmed: 24 10 2019
medline: 11 8 2021
entrez: 24 10 2019
Statut: ppublish

Résumé

Acute administration of [Lys5,Me,Leu9,Nle10]-NKA(4-10) (LMN-NKA) produces contractions of the detrusor and rectum with voiding in intact and acutely spinal cord injured (SCI) rats. In the current study, the ability of LMN-NKA (10 μg/kg or 100 μg/kg, subcutaneous [SC], twice a day [bid]) or vehicle to induce voiding and defecation in chronic SCI rats was examined across 30 days. After the last day of administration, voiding response rates and bladder pressure (BP) responses to LMN-NKA (intravenous [IV] and SC) were evaluated under anesthesia. In conscious rats, LMN-NKA (100 μg/kg) produced dose-dependent micturition within 5 min, with response rates >90%, and voiding efficiency >80% in males and >60% in females, which remained stable across the 1-month test period. Similarly, LMN-NKA administration rapidly induced defecation, which also remained stable. Under anesthesia, LMN-NKA increased BP, voiding efficiency, and voiding response rates, which reached 100% at 3 and 10 μg/kg IV in males and females, respectively. SC administration produced 100% response rates in males (30 μg/kg) but only 71% in females (100 μg/kg). Efficacy in rats chronically treated with LMN-NKA was similar to naïve and vehicle-treated rats, except for reduced voiding efficiency in chronically dosed female rats (100 μg/kg). No differences in bladder weights or collagen-to-smooth muscle ratios in histological sections were seen between the groups. Thus neither tolerance, nor sensitization, to LMN-NKA-induced micturition and defecation occurs with chronic administration in rats with chronic SCI. Efficacy was higher in male than in female rats.

Identifiants

pubmed: 31642371
doi: 10.1089/neu.2019.6676
pmc: PMC7071061
doi:

Substances chimiques

Peptide Fragments 0
Receptors, Neurokinin-2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

868-876

Références

J Pharmacol Exp Ther. 1996 Oct;279(1):423-34
pubmed: 8859022
J Pharmacol Exp Ther. 1986 Mar;236(3):819-31
pubmed: 2419545
Clin Exp Pharmacol Physiol. 2003 Sep;30(9):632-9
pubmed: 12940880
Naunyn Schmiedebergs Arch Pharmacol. 2018 Mar;391(3):299-308
pubmed: 29279967
J Neurotrauma. 2018 May 1;35(9):1079-1090
pubmed: 29205096
Neural Regen Res. 2019 Feb;14(2):222-226
pubmed: 30531001
Am J Physiol. 1986 Aug;251(2 Pt 2):R250-7
pubmed: 3740305
Br J Pharmacol. 2001 Sep;134(1):215-23
pubmed: 11522614
J Pharmacol Exp Ther. 2018 Jul;366(1):136-144
pubmed: 29728445
Eur J Pharmacol. 1996 Dec 30;318(2-3):419-24
pubmed: 9016933
Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):163-173
pubmed: 27889808
Am J Physiol Regul Integr Comp Physiol. 2005 Nov;289(5):R1307-18
pubmed: 15994373
J Pharmacol Exp Ther. 2008 Jan;324(1):170-8
pubmed: 17959748
Exp Neurol. 2018 Aug;306:169-176
pubmed: 29753647
Eur J Pharmacol. 2018 Jan 15;819:261-269
pubmed: 29237540
Am J Physiol Regul Integr Comp Physiol. 2012 Oct 1;303(7):R737-47
pubmed: 22874422
BJU Int. 2017 Feb;119(2):333-341
pubmed: 27431329
Am J Physiol Regul Integr Comp Physiol. 2015 Jun 15;308(12):R1021-33
pubmed: 25855310
Exp Neurol. 2019 Oct;320:113009
pubmed: 31299180
Ann Biomed Eng. 2005 Aug;33(8):1078-89
pubmed: 16133916
Neurourol Urodyn. 2017 Apr;36(4):1061-1068
pubmed: 27490041
Naunyn Schmiedebergs Arch Pharmacol. 2018 Sep;391(9):907-914
pubmed: 29858647

Auteurs

Lesley Marson (L)

Dignify Therapeutics LLC, Research Triangle Park, North Carolina.

Raymond Keast Piatt (RK)

Dignify Therapeutics LLC, Research Triangle Park, North Carolina.

Mary A Katofiasc (MA)

Dignify Therapeutics LLC, Research Triangle Park, North Carolina.

Carol Bobbitt (C)

Dignify Therapeutics LLC, Research Triangle Park, North Carolina.

Karl B Thor (KB)

Dignify Therapeutics LLC, Research Triangle Park, North Carolina.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH